CLOs on the Move

Encore Health Resources

www.encorehealthresources.com

 
Encore Health Resources is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

E P Radiological Svc

E P Radiological Svc is a Canoga Park, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

MyHealth Centre

MyHealth Centre is a unique collaborative partnership of medical professionals and health care industry experts established in order to deliver quality and innovation in patient care. MyHealth Centre is a leading manager of independently owned diagnostic imaging facilities in Ontario. We currently manage over 25 Independent Health Facilities (IHFs) with agreements to develop additional IHF licenses.

Providence Health & Services

Providence Health & Services is a non-profit, Catholic health care system operating multiple hospitals across eight states, with headquarters in Renton, Washington.

Pines Of Sarasota

Pines Of Sarasota is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.